Eupraxia Pharmaceuticals Inc. (EPRX)
| Market Cap | 431.88M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -46.98M |
| Shares Out | 65.33M |
| EPS (ttm) | -1.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 794,007 |
| Open | 6.43 |
| Previous Close | 6.41 |
| Day's Range | 6.31 - 6.70 |
| 52-Week Range | 4.40 - 9.32 |
| Beta | 1.48 |
| Analysts | Strong Buy |
| Price Target | 16.28 (+146.85%) |
| Earnings Date | Aug 11, 2026 |
About EPRX
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company’s product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for EPRX stock is "Strong Buy." The 12-month stock price target is $16.28, which is an increase of 146.85% from the latest price.
News
Oppenheimer starts Eupraxia at Outperform, sees upside from EoE
Oppenheimer analyst Jay Olson initiated coverage of Eupraxia Pharmaceuticals (EPRX) with an Outperform rating and $17 price target The firm said its price target reflects the differentiated potential ...
Eupraxia Pharmaceuticals initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Eupraxia Pharmaceuticals (EPRX) with an Outperform rating and $17 price target
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders
VANCOUVER, British Columbia, June 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging...
Eupraxia Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
A novel, long-acting injectable therapy for EoE shows strong efficacy and safety, with up to 80% clinical remission at six months and sustained benefits for a year. Expansion into related GI conditions and a robust financial runway support continued development and upcoming pivotal trials.
Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
VANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging it...
Eupraxia Pharmaceuticals initiated with a Buy at Stifel
Stifel initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Buy rating and $25 price target Eupraxia is validating its Diffusphere platform starting with a well-known corticosteroid, fluticaso...
Eupraxia Pharmaceuticals Slides: Corporate presentation
Eupraxia Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
Eupraxia Pharmaceuticals reports Q1 net loss ($12.7M) vs. ($6.8M) last year
The Company had cash and cash equivalents of $58.5M and short-term investments of $80.4M as of March 31, up from a cash balance of $80.6M at the end of the…
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indicat...
Eupraxia Pharmaceuticals Earnings release: Q1 2026
Eupraxia Pharmaceuticals released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Eupraxia Pharmaceuticals Registration statement: Q1 2026
Eupraxia Pharmaceuticals filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Eupraxia Pharmaceuticals Registration statement: Q1 2026
Eupraxia Pharmaceuticals filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
EoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue damage in EoE patients. Sub scores of EoEHSS are reported to specifically evaluate the tissue inflammat...
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)
EREFS is a standardized visual scoring system that gastroenterologists use when performing an endoscopy in EoE patients to assess the severity of inflammation and fibrosis in the esophagus EREFS data ...
Eupraxia Pharmaceuticals names Dr. Jeymi Tambiah as Chief Medical Officer
Eupraxia Pharmaceuticals (EPRX) announced the appointment of Dr. Jeymi Tambiah as Chief Medical Officer as well as the retirement of Dr. Mark Kowalski, Eupraxia’s current CMO. Dr. Jeymi Tambiah is
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging it...
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging ...
Eupraxia reports 9-month tissue symptom data from Phase 1b/2a Resolve trial
Eupraxia Pharmaceuticals (EPRX) announced 36-week tissue health and symptom data from patients in the highest dose cohort from its ongoing Phase 1b/2a part of the Resolve trial evaluating EP-104GI for
Eupraxia Pharmaceuticals Transcript: Bloom Burton & Co. Healthcare Investor Conference 2026
Fresh clinical data show rapid, durable remission in EoE with a novel, locally delivered steroid, supported by strong safety and histology results. Well-funded through 2028, the company is expanding into benign esophageal strictures and fibrostenotic Crohn’s, targeting large, underserved GI markets.
Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst
William Blair on Monday initiated coverage on Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), a clinical-stage biotechnology company focused on the development of locally delivered, extended-release pro...
Eupraxia Pharmaceuticals initiated with an Outperform at William Blair
William Blair initiated coverage of Eupraxia Pharmaceuticals (EPRX) with an Outperform rating and $14 fair value estimate. Eupraxia is a clinical-stage biotechnology company developing extended-releas...
Eupraxia Pharmaceuticals’ esophagitis candidate shows symptom decrease
Eupraxia Pharmaceuticals (EPRX) announced positive symptom data from patients in the two highest dose cohorts from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatme...
Eupraxia price target lowered to $11 from $12 at H.C. Wainwright
H.C. Wainwright analyst Brandon Folkes lowered the firm’s price target on Eupraxia Pharmaceuticals (EPRX) to $11 from $12 and keeps a Buy rating on the shares. The firm adjusted the
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging i...
Eupraxia Pharmaceuticals Registration statement: Q4 2025
Eupraxia Pharmaceuticals filed a registration statement on March 12, 2026, providing details about a securities offering with the SEC.